How big is Regeneron Pharmaceuticals, Inc.?

As of Jun 18, Regeneron Pharmaceuticals, Inc. has a market capitalization of $69.29 billion, with net sales of $14.09 billion and a net profit of $4.50 billion over the last four quarters.

Market Cap: As of Jun 18, Regeneron Pharmaceuticals, Inc. has a market capitalization of 69,289.17 million, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Regeneron Pharmaceuticals, Inc. reported net sales of 14,085.70 million and a net profit of 4,499.30 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 29,353.60 million and total assets of 37,852.40 million.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious medical conditions. As of March 2025, it reported net sales of $3.03 billion and a market cap of approximately $69.29 billion.

Overview:<BR>Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a large-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,029 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 809 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 69,289.17 Million (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00 <BR>Dividend Yield: 0.28% <BR>Debt Equity: -0.22 <BR>Return on Equity: 14.39% <BR>Price to Book: 2.36<BR><BR>Contact Details:<BR>Address: 777 Old Saw Mill River Rd, TARRYTOWN NY: 10591-6717 <BR>Tel: 1 914 8477000 <BR>Website: https://www.regeneron.com/

Should I buy, sell or hold Regeneron Pharmaceuticals, Inc.?

Who are in the management team of Regeneron Pharmaceuticals, Inc.?

As of March 2022, the management team of Regeneron Pharmaceuticals includes Dr. P. Roy Vagelos (Chairman), Dr. Leonard Schleifer (CEO), and Dr. George Yancopoulos (CSO), along with several independent directors such as Dr. Bonnie Bassler and Dr. Michael Brown.

As of March 2022, the management team of Regeneron Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. P. Roy Vagelos, Chairman of the Board and Director<BR>- Dr. Leonard Schleifer, President, Chief Executive Officer, and Director<BR>- Dr. George Yancopoulos, President, Chief Scientific Officer, and Director<BR><BR>Additionally, the Board of Directors features several independent directors, including Dr. Bonnie Bassler, Dr. Michael Brown, Dr. N. Anthony Coles, Dr. Joseph Goldstein, and Ms. Christine Poon.

Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?

As of August 1, 2025, Regeneron Pharmaceuticals is considered fairly valued with a P/E ratio of 16, lower than some peers like Eli Lilly and Johnson & Johnson, but has underperformed the S&P 500 with a return of -47.43% over the past year.

As of 1 August 2025, the valuation grade for Regeneron Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 16, an EV to EBITDA of 13.64, and a Price to Book Value of 2.29. <BR><BR>In comparison to peers, Regeneron has a P/E ratio lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, suggesting it may be more attractively priced relative to these competitors. However, it is slightly higher than Merck & Co., Inc. at 15.68, which is also considered attractive. Notably, Regeneron's stock has underperformed against the S&P 500 over the past year, with a return of -47.43% compared to the index's 17.14%, reinforcing the notion that the stock may be fairly valued in light of its recent performance.

Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, Regeneron Pharmaceuticals shows a neutral technical trend with mixed signals, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 3 October 2025, the technical trend for Regeneron Pharmaceuticals, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a bullish trend weekly but mildly bearish monthly. Moving averages are mildly bearish on the daily chart. Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, Regeneron has underperformed the S&P 500 significantly over the longer term, with a year-to-date return of -17.81% compared to the S&P 500's 14.18%, and a one-year return of -42.19% versus the S&P 500's 17.82%.